Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: a retrospective study

S Yang, W Zhang, Q Chen, Q Guo - Cancer Management and …, 2020 - Taylor & Francis
… A number of studies have shown that smoking has a certain adverse effect on the development
of lung cancer and is a prognostic factor for the treatment of lung cancer. Citation21 – …

… results of NRG oncology RTOG 0617: standard-versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non–small-cell lung cancer

JD Bradley, C Hu, RR Komaki, GA Masters… - Journal of Clinical …, 2020 - ascopubs.org
detrimental, factors predictive of better OS on multivariable analysis include tumor locations
away from the heart, 17 treatment … , 18 smaller PTVs (or gross tumor volumes), and reduction …

[HTML][HTML] Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

L Peng, Y Wang, F Liu, X Qiu, X Zhang, C Fang… - Cancer Immunology …, 2020 - Springer
… Although the preciseness of lung cancer treatment has improved significantly in recent
years, NSCLC remains challenging. The emergence of PD-1 inhibitors has brought hope to …

[HTML][HTML] Chinese herbal medicine combined with first-generation EGFR-TKIs in treatment of advanced non-small cell lung cancer with EGFR sensitizing mutation: a …

Y Lu, C Sun, L Jiao, Y Liu, Y Gong, L Xu - Frontiers in Pharmacology, 2021 - frontiersin.org
… The current study sought to assess benefits and negative effects of CHM as a combination
therapy with first-generation EGFR-TKIs in advanced NSCLC patients harboring an active …

[PDF][PDF] MAGI1-IT1 stimulates proliferation in non-small cell lung cancer by upregulating AKT1 as a ceRNA.

G Zhang, HX Chen, SN Yang… - European Review for …, 2020 - europeanreview.org
… suppresses cell adhesion and metastasis of lung cancer cells A549 … Our findings uncovered
a negative interaction between … target gene of miR-412-3p, presenting a negative correlation …

The novel proautophagy anticancer drug ABTL0812 potentiates chemotherapy in adenocarcinoma and squamous nonsmall cell lung cancer

A López‐Plana, P Fernández‐Nogueira… - … Journal of Cancer, 2020 - Wiley Online Library
… Thus, there remains an urgent need for designing new efficacious drug combinations to
combat this disease without increasing unwanted toxic side effects. In our study, we showed how …

Advances in systemic therapy for non-small cell lung cancer

M Miller, N Hanna - Bmj, 2021 - bmj.com
… Potential side effects of immunotherapy differ from those of traditional cytotoxic chemotherapy.
Immune mediated inflammation can occur in any part of the body, examples of which …

Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives

EN Imyanitov, AG Iyevleva, EV Levchenko - Critical reviews in oncology …, 2021 - Elsevier
… genomic region, has a risk of obtaining false-negative results when the analyzed sample
is not sufficiently enriched by tumor cells. Current guidelines encourage the use of mutation-…

[HTML][HTML] Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis

S Jiang, L Huang, H Zhen, P Jin, J Wang, Z Hu - BMC cancer, 2021 - Springer
… The carboplatin-containing regimen was also correlated with more adverse impacts on the
… regimen was associated with adverse gastrointestinal effects and neurotoxicity. Recently, …

A biobank of small cell lung cancer CDX models elucidates inter-and intratumoral phenotypic heterogeneity

KL Simpson, R Stoney, KK Frese, N Simms, W Rowe… - Nature Cancer, 2020 - nature.com
… Mice were observed for a period of time after dose to ensure no adverse effects were
seen. Tumors were measured twice a week by caliper until they reached four times initial …